Eli Lilly to sign $2 billion deal for AI drug development with Hong Kong's Insilico Medicine, FT says

Eli Lilly will sign a $2 billion deal with Hong Kong-listed AI drug-discovery firm Insilico Medicine, the Financial Times reported. The agreement highlights major pharma investment into AI-enabled discovery, likely boosting Insilico's valuation and increasing sector investor and M&A interest.

Analysis

Eli Lilly will sign a $2 billion deal with Hong Kong-listed AI drug-discovery firm Insilico Medicine, the Financial Times reported. The agreement highlights major pharma investment into AI-enabled discovery, likely boosting Insilico's valuation and increasing sector investor and M&A interest.